{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:01:20Z","timestamp":1762761680622},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate the efficacy and safety of CyberKnife Stereotactic Body Radiation Therapy (SBRT) in the treatment of adrenal gland metastases (AGM), we designed a large-scale multicenter retrospective study to report the safety and efficacy of SBRT for inoperable AGM. In this study, 75 (61 males, 14 females) patients with 84 AGM and Karnofsky performance score \u226570 were treated by SBRT from October 2006 to January 2017. Of these, the purpose of treatment were controlling all known metastatic sites for 21 patients while 54 for palliation of bulky adrenal metastases. The efficacy and safety of SBRT were evaluated during follow-up. Potential factors predictive of local control (LC) and overall survival (OS) were identified by univariate and multivariate analysis. Median follow-up time was 12.7 months (range 1.8\u201396.4). The complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) rates were 23.8%, 23.8%, 31.0% and 21.4%, respectively. The 0.5, 1, and 2-year LC rates were 93.6%, 83.8%, and 62.1%, respectively; OS rates on the same follow-up intervals were 93.7%, 62.5%, and 49.6%, respectively, and the corresponding PFS rates were 48.5%, 33.9%, and 16.0%, respectively. The treatment was well tolerated with 2 patients reporting grade-3 diarrhea and fatigue, respectively. Multivariate analysis showed that simultaneous treatment of SBRT for other metastatic lesions, the number of AGM, initiation of systemic therapy, and the maximum diameter of AGM were predictive of LC rates. Moreover, patients with AGM\u2009&lt;\u20095\u2009cm had a superior OS compared with those with AGM\u2009\u2265\u20095\u2009cm (28.0 months vs. 17.6 months, P\u2009=\u20090.032). SBRT is an effective therapeutic option for treatment of AGM with high LC rates with minimal toxicity.<\/jats:p>","DOI":"10.1038\/s41598-020-64770-2","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T10:08:48Z","timestamp":1589278128000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) for adrenal gland metastases: A multi-center retrospective study from China"],"prefix":"10.1038","volume":"10","author":[{"given":"Xianzhi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqing","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongchun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"issue":"7","key":"64770_CR1","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00268-001-0029-0","volume":"25","author":"LM Brunt","year":"2001","unstructured":"Brunt, L. M. et al. Adrenal incidentaloma. World J Surg. 25(7), 905\u2013913 (2001).","journal-title":"World J Surg."},{"key":"64770_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fonc.2015.00185","volume":"5","author":"A Desai","year":"2015","unstructured":"Desai, A. et al. A Retrospective Review of CyberKnife Stereotactic Body Radiotherapy for Adrenal Tumors (Primary and Metastatic): Winthrop University Hospital Experience. Front Oncol. 5, 185 (2015).","journal-title":"Front Oncol."},{"issue":"6","key":"64770_CR3","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1067\/msy.2001.118369","volume":"130","author":"JT Lenert","year":"2001","unstructured":"Lenert, J. T. et al. Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy. Surgery. 130(6), 1060\u20137 (2001).","journal-title":"Surgery."},{"issue":"7","key":"64770_CR4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/02841860600904854","volume":"45","author":"M Hoyer","year":"2006","unstructured":"Hoyer, M. et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol (Madr). 45(7), 823\u201330 (2006).","journal-title":"Acta Oncol (Madr)."},{"issue":"3","key":"64770_CR5","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ijrobp.2011.08.036","volume":"83","author":"MT Milano","year":"2012","unstructured":"Milano, M. T. et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 83(3), 878\u201386 (2012).","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"64770_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.radonc.2013.05.024","volume":"107","author":"J Widder","year":"2013","unstructured":"Widder, J. et al. Pulmonary oligometastases: Metastasectomy or stereotactic ablative radiotherapy? Radiother Oncol. 107(3), 409\u201313 (2013).","journal-title":"Radiother Oncol."},{"issue":"2","key":"64770_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.lungcan.2015.05.002","volume":"89","author":"CD Corso","year":"2015","unstructured":"Corso, C. D. et al. Racial disparities in the use of SBRT for treating early - stage lung cancer. Lung Cancer. 89(2), 133\u20138 (2015).","journal-title":"Lung Cancer."},{"issue":"4","key":"64770_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s12029-017-9990-1","volume":"49","author":"H Qiu","year":"2018","unstructured":"Qiu, H. et al. SBRT for Hepatocellular Carcinoma: 8 - Year Experience from a Regional Transplant Center. J Gastrointest Cancer. 49(4), 463\u2013469 (2018).","journal-title":"J Gastrointest Cancer."},{"issue":"9","key":"64770_CR9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00066-018-1306-2","volume":"194","author":"R Mazzola","year":"2018","unstructured":"Mazzola, R. et al. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery. Strahlenther Onkol. 194(9), 835\u2013842 (2018).","journal-title":"Strahlenther Onkol."},{"issue":"1","key":"64770_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-017-0872-2","volume":"12","author":"P Jiang","year":"2017","unstructured":"Jiang, P. et al. Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial. Radiat Oncol. 12(1), 138 (2017).","journal-title":"Radiat Oncol."},{"key":"64770_CR11","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.2147\/OTT.S107106","volume":"9","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Clinical study on the influence of motion and other factors on stereotactic radiotherapy in the treatment of adrenal gland tumor. Onco Targets Ther. 9, 4295\u20134299 (2016).","journal-title":"Onco Targets Ther."},{"issue":"8","key":"64770_CR12","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1118\/1.3438081","volume":"37","author":"SH Benedict","year":"2010","unstructured":"Benedict, S. H. et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 37(8), 4078\u20134101 (2010).","journal-title":"Med Phys."},{"key":"64770_CR13","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Publish. 2009."},{"issue":"2","key":"64770_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejca.2008.10.027","volume":"45","author":"J Bogaerts","year":"2009","unstructured":"Bogaerts, J. et al. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer. 45(2), 248\u2013260 (2009).","journal-title":"Eur J Cancer."},{"issue":"3","key":"64770_CR15","first-page":"407","volume":"7","author":"Z Wang","year":"2015","unstructured":"Wang, Z. et al. Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases. J Thorac Dis. 7(3), 407\u2013412 (2015).","journal-title":"J Thorac Dis."},{"key":"64770_CR16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2147\/OTT.S58409","volume":"7","author":"ZY Yuan","year":"2014","unstructured":"Yuan, Z. Y. et al. Stereotactic body radiation therapy using the CyberKnife(\u00ae) system for patients with liver metastases. Onco Targets Ther. 7, 915\u2013923 (2014).","journal-title":"Onco Targets Ther."},{"key":"64770_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep37987","volume":"6","author":"Z Wang","year":"2016","unstructured":"Wang, Z. et al. Stereotactic body radiation therapy induces fast tumor control and symptom relief in patients with iliac lymph node metastasis. Sci Rep. 6, 37987 (2016).","journal-title":"Sci Rep."},{"issue":"1","key":"64770_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-018-1152-5","volume":"13","author":"X Zhao","year":"2018","unstructured":"Zhao, X. et al. Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer. Radiat Oncol. 13(1), 205 (2018).","journal-title":"Radiat Oncol."},{"issue":"1","key":"64770_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijrobp.2008.10.079","volume":"75","author":"S Chawla","year":"2009","unstructured":"Chawla, S. et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys. 75(1), 71\u201375 (2009).","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"6","key":"64770_CR20","first-page":"484","volume":"20","author":"E Ippolito","year":"2015","unstructured":"Ippolito, E. et al. SBRT: A viable option for treating adrenal gland metastases. Reports Pract Oncol Radiother J Gt Cancer Cent Pozn Polish Soc. Radiat Oncol. 20(6), 484\u2013490 (2015).","journal-title":"Radiat Oncol."},{"issue":"4","key":"64770_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00066-011-2192-z","volume":"187","author":"R Holy","year":"2011","unstructured":"Holy, R. et al. Stereotactic Body Radiation Therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlentherapie und Onkol. 187(4), 245\u2013251 (2011).","journal-title":"Strahlentherapie und Onkol."},{"key":"64770_CR22","doi-asserted-by":"publisher","first-page":"153303381880998","DOI":"10.1177\/1533033818809983","volume":"17","author":"N Katoh","year":"2018","unstructured":"Katoh, N. et al. Real-time tumor-tracking radiotherapy and general stereotactic body radiotherapy for adrenal metastasis in patients with oligometastasis. Technol Cancer Res Treat. 17, 1533033818809983 (2018).","journal-title":"Technol Cancer Res Treat."},{"key":"64770_CR23","doi-asserted-by":"crossref","unstructured":"Burjakow K. et al. Fractionated stereotactic radiation therapy for adrenal metastases: contributing to local tumor control with low toxicity. 195(3),236-245 (2018).","DOI":"10.1007\/s00066-018-1390-3"},{"key":"64770_CR24","doi-asserted-by":"crossref","unstructured":"Toesca D. A. S. et al. Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity. Adv Radiat Oncol. 3(4),621\u2013629 (2018).","DOI":"10.1016\/j.adro.2018.05.006"},{"issue":"3","key":"64770_CR25","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.21873\/anticanres.12788","volume":"38","author":"D Buergy","year":"2018","unstructured":"Buergy, D. et al. Treatment of adrenal metastases with conventional or hypofractionated image-guided radiation therapy - patterns and outcomes. Anticancer Res. 38(3), 4789\u20134796 (2018).","journal-title":"Anticancer Res."},{"issue":"4","key":"64770_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.adro.2017.07.011","volume":"2","author":"K Plichta","year":"2017","unstructured":"Plichta, K. et al. SBRT to adrenal metastases provides high local control with minimal toxicity. Adv Radiat Oncol. 2(4), 581\u2013587 (2017).","journal-title":"Adv Radiat Oncol."},{"issue":"9","key":"64770_CR27","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s12094-017-1654-x","volume":"19","author":"BY Yuan","year":"2017","unstructured":"Yuan, B. Y. et al. Radiotherapy for adrenal gland metastases from hepatocellular carcinoma. Clin Transl Oncol. 19(9), 1154\u20131160 (2017).","journal-title":"Clin Transl Oncol."},{"issue":"3","key":"64770_CR28","first-page":"e1120","volume":"9","author":"A Haidenberger","year":"2017","unstructured":"Haidenberger, A. et al. Robotic radiosurgery for adrenal gland metastases. Cureus. 9(3), e1120 (2017).","journal-title":"Cureus."},{"issue":"3","key":"64770_CR29","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/j.prro.2016.09.005","volume":"7","author":"WW Chance","year":"2017","unstructured":"Chance, W. W. et al. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol. 7(3), e195\u2013e203 (2017).","journal-title":"Pract Radiat Oncol."},{"issue":"1","key":"64770_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4143\/crt.2016.057","volume":"49","author":"C Franzese","year":"2017","unstructured":"Franzese, C. et al. Minimally invasive stereotactical radio-ablation of adrenal metastases as an alternative to surgery. Cancer Res Treat. 49(1), 20\u201328 (2017).","journal-title":"Cancer Res Treat."},{"issue":"3","key":"64770_CR31","doi-asserted-by":"publisher","first-page":"e0152642","DOI":"10.1371\/journal.pone.0152642","volume":"11","author":"J Jung","year":"2016","unstructured":"Jung, J. et al. Radiotherapy for adrenal metastasis from hepatocellular carcinoma: a multi-institutional retrospective study (KROG 13-05). PLoS One. 11(3), e0152642 (2016).","journal-title":"PLoS One."},{"key":"64770_CR32","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijrobp.2018.06.105","volume":"102","author":"D Palma","year":"2018","unstructured":"Palma, D. et al. Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial. Int J Radiat Oncol Biol Phys. 102, S3 (2018).","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"64770_CR33","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.ijrobp.2018.08.050","volume":"102","author":"DR Gomez","year":"2018","unstructured":"Gomez, D. R. et al. Local consolidative therapy (LCT) improves overall survival (OS) compared to maintenance therapy\/observation in oligometastatic non-small cell lung cancer (NSCLC): final results of a multicenter, randomized, controlled phase 2 trial. Int J Radiat Oncol Biol Phys. 102, 1604 (2018).","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"7","key":"64770_CR34","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/cncr.20539","volume":"101","author":"H Onishi","year":"2004","unstructured":"Onishi, H. et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 101(7), 1623\u20131631 (2004).","journal-title":"Cancer."},{"issue":"4","key":"64770_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.rpor.2013.05.005","volume":"19","author":"AR Filippi","year":"2014","unstructured":"Filippi, A. R. et al. Is stereotactic ablative radiotherapy an alternative to surgery in operable stage I non-small cell lung cancer? Reports Pract Oncol Radiother. 19(4), 275\u2013279 (2014).","journal-title":"Reports Pract Oncol Radiother."},{"issue":"2","key":"64770_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.radonc.2011.05.033","volume":"101","author":"A Takeda","year":"2011","unstructured":"Takeda, A. et al. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 101(2), 255\u2013259 (2011).","journal-title":"Radiother Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64770-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64770-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64770-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T10:29:07Z","timestamp":1670322547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64770-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["64770"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-64770-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"28 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7836"}}